1. Articles in category: Genomics

    1-24 of 189 1 2 3 4 5 6 7 8 »
    1. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    2. Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Next-generation sequencing reveals germline mutations in an infant with synchronous occurrence of nephro- and neuroblastoma.

      Pediatr Hematol Oncol. 2016 May;33(4):264-75

      Authors: Theruvath J, Russo A, Kron B, Paret C, Wingerter A, El Malki K, Neu MA, Alt F, Staatz G, Stein R, Seidmann L, Prawitt D, Faber J

      Read Full Article
      Mentions: ALK
    3. Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

      Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.

      Sci Data. 2017 Mar 28;4:170033

      Authors: Harenza JL, Diamond MA, Adams RN, Song MM, Davidson HL, Hart LS, Dent MH, Fortina P, Reynolds CP, Maris JM

      Abstract Neuroblastoma cell lines are an important and cost-effective model used to study oncogenic drivers of the disease.

      Read Full Article
      Mentions: ALK MYCN
    4. Neuroblastoma treatment in the post-genomic era.

      Neuroblastoma treatment in the post-genomic era.

      J Biomed Sci. 2017 Feb 08;24(1):14

      Authors: Esposito MR, Aveic S, Seydel A, Tonini GP

      Abstract Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics.

      Read Full Article
      Mentions: Treatment ALK MYCN
    5. New assay shows promise to advance personalized therapy for cancer patients

      New assay shows promise to advance personalized therapy for cancer patients

      ( Elsevier Health Sciences ) The National Cancer Institute's NCI-MATCH (Molecular Analysis for Therapy Choice) is a large, ongoing clinical trial that matches tumors to therapies based on the tumor's genetic characteristics. A report in The Journal of Molecular Diagnostics confirms that the assay tailored for this trial is highly sensitive for detecting genetic mutations from a variety of tumor tissue and, for the first time, has been reproduced with accuracy by multiple clinical laboratories, laying the groundwork for future clinical utility.

      Read Full Article
      Mentions: Diagnostics
    6. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

      Eur J Cancer. 2016 Dec 26;72:177-185

      Authors: Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ

      Read Full Article
      Mentions: INRG
    7. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

      "However, recent studies have shown that the mutational burden increases at relapse, likely as a result of clonal evolution of mutation-carrying cells during primary treatment. To inform the development of personalized therapies, we sought to further define the frequency of potentially actionable mutations in neuroblastoma, both at diagnosis and after chemotherapy. We performed a retrospective study to determine mutation frequency, the only inclusion criterion being availability of cancer gene panel sequencing data from Foundation Medicine. We analyzed 151 neuroblastoma tumor samples: 44 obtained at diagnosis, 42 at second look surgery or biopsy for stable disease after chemotherapy, and 59 at ...

      Read Full Article
      Mentions: ALK
    8. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

      Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

      Semin Pediatr Surg. 2016 Oct;25(5):257-264

      Authors: Newman EA, Nuchtern JG

      Abstract Neuroblastoma is an embryonic cancer of neural crest cell lineage, accounting for up to 10% of all pediatric cancer. The clinical course is heterogeneous ranging from spontaneous regression in neonates to life-threatening metastatic disease in older children.

      Read Full Article
      Mentions: Treatment
    9. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.

      "Analysis of 5-hydroxymethylcytosine and ENCODE data indicate that at least five of these nine genes have an increase in 5-hydroxymethylcytosine and a more open chromatin structure in hypoxia versus normoxia and are putative targets of hypoxia inducible factor (HIF) as they contain HIF binding sites in their regulatory regions. Four of these genes are key components of the glycolytic pathway and another three are directly involved in cellular metabolism. We experimentally validated our computational findings demonstrating that seven of the nine genes are significantly up-regulated in response to hypoxia in the four neuroblastoma cell lines tested. This compact and robustly ...

      Read Full Article
      Mentions: Genetics
    10. Parents of children with cancer value sequencing results, even if non-actionable

      "There is a general, ethical inclination to be reluctant to disclose sequencing information without clear clinical utility, especially when children are involved," said Dr. Malek, who presented the research. "However, our study showed that parents find this information useful in a much broader way than clinicians might expect," she said.  For example, many parents cited psychological benefits to receiving the information. "Almost all of the parents we interviewed wanted to know where the cancer had come from," Dr. Malek explained. "They hoped that evidence of a genetic cause would show that they had not caused it through any action or ...

      Read Full Article
      Mentions: Genetics
    11. A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group.

      A family-based study of gene variants and maternal folate and choline in neuroblastoma: a report from the Children's Oncology Group.

      Cancer Causes Control. 2016 Aug 19;

      Authors: Mazul AL, Siega-Riz AM, Weinberg CR, Engel SM, Zou F, Carrier KS, Basta PV, Vaksman Z, Maris JM, Diskin SJ, Maxen C, Naranjo A, Olshan AF

      Read Full Article
      Mentions: COG
    12. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

      "We show for the first time that high expression of TFAP4 in primary neuroblastoma patients is associated with poor clinical outcome. siRNA-mediated suppression of TFAP4 in MYCN-expressing neuroblastoma cells led to inhibition of cell proliferation and migration. Chromatin immunoprecipitation assay demonstrated that TFAP4 expression is positively regulated by MYCN. Microarray analysis identified genes regulated by both MYCN and TFAP4 in neuroblastoma cells, including Phosphoribosyl-pyrophosphate synthetase-2 (PRPS2) and Syndecan-1 (SDC1), which are involved in cancer cell proliferation and metastasis. Overall this study suggests a regulatory circuit in which MYCN by elevating TFAP4 expression, cooperates with it to control a specific set ...

      Read Full Article
      Mentions: MYCN
    13. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience

      "Eighty-nine percent (39/44) of respondents reported hoping participation would help find cures for future patients, while 59% (26/44) hoped it would increase their/their child's chance of cure. Most had few concerns about GTP, but 12% (5/43) worried they would learn their/their child's cancer was less treatable or more aggressive than previously thought. Sixty-four percent (29/45) reported feeling their participation had helped others and 44% (20/45) felt they had helped themselves/their own child, despite only one substudy subject receiving targeted therapy matched to GTP findings. Fifty-four percent (21/39) wished to ...

      Read Full Article
    14. Does using biomarker to select patients for Phase 1 trials improve efficacy?

      Does using biomarker to select patients for Phase 1 trials improve efficacy?

      "These results argue strongly for the enrichment of phase 1 clinical trials with biomarker selection for targeted therapies. However, rigid exclusion based on biomarkers that have not been proven clinically could prove counterproductive in some cases," the authors conclude."

      Read Full Article
    15. Neuroblastoma: A Tough Nut to Crack.

      "These advances have resulted in a growing population of long-term survivors of neuroblastoma. Examination of the late effects and second malignant neoplasms (SMNs) in both older generations of survivors and more recently treated survivors will inform both design of future trials and surveillance guidelines for long-term follow-up. As a consequence of advances in understanding of the biology of neuroblastoma, successful clinical trials, and refined understanding of the late effects and SMNs of survivors, the promise of precision medicine is becoming a reality for patients with neuroblastoma."

      Read Full Article
      Mentions: Treatment MYCN
    16. Landmark Lions project to provide genome sequencing to hundreds of Aussie kids with cancer

      ( Garvan Institute of Medical Research ) Hundreds of Australian children with high-risk cancer will have access to new genome sequencing technologies that could guide their treatment, following the announcement today of substantial Lions Club funding for the Lions Kids Cancer Genome Project -- an important new component of the Zero Childhood Cancer Program for diagnosis and treatment of childhood cancer.

      Read Full Article
      Mentions: Genetics
    17. Neuroblastoma and Its Zebrafish Model.

      Neuroblastoma and Its Zebrafish Model.

      Adv Exp Med Biol. 2016;916:451-78

      Authors: Zhu S, Thomas Look A

      Abstract Neuroblastoma, an important developmental tumor arising in the peripheral sympathetic nervous system (PSNS), accounts for approximately 10 % of all cancer-related deaths in children. Recent genomic analyses have identified a spectrum of genetic alterations in this tumor.

      Read Full Article
      Mentions: ALK MYCN
    18. Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.

      Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.

      Oncotarget. 2016 May 6;

      Authors: Hsu CL, Chang HY, Chang JY, Hsu WM, Huang HC, Juan HF

      Abstract MYCN, an oncogenic transcription factor of the Myc family, is a major driver of neuroblastoma tumorigenesis.

      Read Full Article
    19. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine.

      Paediatr Drugs. 2016 May 3;

      Authors: Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH

      Abstract It is well known that drug responses differ among patients with regard to dose requirements, efficacy, and adverse drug reactions (ADRs). The differences in drug responses are partially explained by genetic variation.

      Read Full Article
    20. Genetics Home Reference: neuroblastoma

      Neuroblastoma and other cancers occur when a buildup of genetic mutations in critical genes—those that control cell growth and division (proliferation) or maturation (differentiation)—allow cells to grow and divide uncontrollably to form a tumor. In most cases, these genetic changes are acquired during a person's lifetime and are called somatic mutations. Somatic mutations are present only in certain cells and are not inherited.

      Read Full Article
      Mentions: ALK MYCN PHOX2B
    21. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.

      "Crizotinib, the first clinically approved ALK inhibitor for the treatment of ALK-positive lung cancer has had less dramatic responses in neuroblastoma. Here we investigate the efficacy of a second-generation ALK inhibitor, brigatinib, in a neuroblastoma setting. Employing neuroblastoma cell lines, mouse xenograft and Drosophila melanogaster model systems expressing different constitutively active ALK variants, we show clear and efficient inhibition of ALK activity by brigatinib. Similar abrogation of ALK activity was observed in vitro employing a set of different constitutively active ALK variants in biochemical assays. These results suggest that brigatinib is an effective inhibitor of ALK kinase activity in ALK ...

      Read Full Article
      Mentions: ALK
    22. New genetic testing for children with neuroblastoma

      New genetic testing for children with neuroblastoma

      "Scientists at the Institute of Cancer Research and Royal Marsden Hospital have developed a new genetic test that will be given to children with solid tumours in an effort to analyse genetic changes in 81 cancer genes, with funding from Christopher Smile.  This is the first stage of an initiative to bring these tests to all children diagnosed with a solid tumour and will look to sample around 400 childhood solid tumours over the next two years. The aim is to use the results from these samples to drive development of clinical trials investigating drugs targeting specific genetic changes in ...

      Read Full Article
    1-24 of 189 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) ALK
    2. (1 articles) MYCN